FDA warns Mike Millenkamp Dairy Cattle that enrofloxacin use not on the approved label in a beef steer violated animal-drug rules.
What happened
FDA inspected the beef cattle growing operation in Earlville, Iowa, on August 2 and 5, 2022. FDA found that the company gave enrofloxacin to a beef steer 10 times over a 30-day period starting about December 21, 2021, to treat Mycoplasma bovis, instead of the approved label's single dose; FDA said this made the drug adulterated (unsafe under the FD&C Act). FDA also said the company did not respond to the Form FDA 483 (inspection observations) issued at the close of the inspection.
What FDA found
Gave enrofloxacin to a beef steer in a way not allowed by the approved label: 10 doses over 30 days to treat Mycoplasma bovis instead of the labeled single dose.
21 CFR 530.3(a); 21 CFR 530.41(a)(10)Because enrofloxacin is a fluoroquinolone and FDA rules prohibit use of fluoroquinolones outside the approved label, FDA said the use made the drug unsafe and adulterated.
FD&C Act § 512(a); § 501(a)(5)Doing an act to the drug after interstate shipment that results in the drug being adulterated is a prohibited act.
FD&C Act § 301(k)
What FDA wants
Within 15 working days of receipt, FDA asks the company to write to its office with the specific steps taken to correct the violations, prevent recurrence, and include related documents. If it cannot complete corrections in that time, it must state why and when it will finish.
Who should pay attention
- beef cattle producers and feedlot operators
- veterinarians who prescribe enrofloxacin for cattle
- beef processors and brands that buy from such operations
This is a summary. Read the original letter on fda.gov.